Botulinum toxin - CKD Bio Corporation
Alternative Names: CKDB-501; CKDB-501A; CKDB-501B; CU-20101Latest Information Update: 13 Sep 2024
At a glance
- Originator CKD Pharmaceuticals
- Class Antispasmodics; Bacterial proteins; Bacterial toxins; Muscle relaxants; Skin disorder therapies; Urologics
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Glabellar lines
- Phase I Muscle spasticity
Most Recent Events
- 11 Jun 2024 Phase-III clinical trials in Glabellar lines in China (Parenteral) (NCT06585696) (CTR20241540)
- 26 Mar 2024 Healis Therapeutics entered into a R&D agrrement with Massachusetts General Hospital and affiliates of Harvard Medical School for clinical development of Botulinum toxin for Psychiatric disorders
- 05 Mar 2024 Healis Therapeutics plans clinical trials for Major Depressive Disorder in the US and the European Union